Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;14(4):781-91.
doi: 10.1208/s12248-012-9388-8. Epub 2012 Aug 4.

Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics

Xin Xu  1 , Yulia Vugmeyster
Affiliations
Review

Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics

Xin Xu et al. AAPS J. 2012 Dec.

Abstract

With the advancement of biotechnology in the last two decades, optimized and novel modalities and platforms of biologic moieties have emerged rapidly in drug discovery pipelines. In addition, new technologies for delivering therapeutic biologics (e.g., needle-free devices, nanoparticle complexes), as well as novel approaches for disease treatments (e.g., stem cell therapy, individualized medicine), continue to be developed. While pharmacokinetic studies are routinely carried out for therapeutic biologics, experiments that elucidate underlying mechanisms for clearance and biodistribution or identify key factors that govern absorption, distribution, metabolism, and excretion (ADME) of biologics often are not thoroughly conducted. Realizing the importance of biologics as therapeutic agents, pharmaceutical industry has recently begun to move the research focus from small molecules only to a blended portfolio consisting of both small molecules and biologics. This trend brings many opportunities for scientists working in the drug disposition research field. In anticipation of these opportunities and associated challenges, this review highlights impact of ADME studies on clinical and commercial success of biologics, with a particular focus on emerging applications and technologies and linkage with mechanistic pharmacokinetic/pharmacodynamic modeling and biomarker research.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Size comparison of a typical small molecule (illustrated by acetaminophen) and an IgG antibody
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Biologics: the role of delivery systems in improved therapy.
    Skalko-Basnet N. Skalko-Basnet N. Biologics. 2014 Mar 19;8:107-14. doi: 10.2147/BTT.S38387. eCollection 2014. Biologics. 2014. PMID: 24672225 Free PMC article. Review.
  • Peptide-Based Supramolecular Hydrogels for Delivery of Biologics.
    Li Y, Wang F, Cui H. Li Y, et al. Bioeng Transl Med. 2016 Sep;1(3):306-322. doi: 10.1002/btm2.10041. Bioeng Transl Med. 2016. PMID: 28989975 Free PMC article.
  • Revolutionizing antiviral therapy with nanobodies: Generation and prospects.
    Mustafa MI, Mohammed A. Mustafa MI, et al. Biotechnol Rep (Amst). 2023 Jun 7;39:e00803. doi: 10.1016/j.btre.2023.e00803. eCollection 2023 Sep. Biotechnol Rep (Amst). 2023. PMID: 37332617 Free PMC article. Review.
  • Comparison of Cyclic and Linear PEG Conjugates.
    Kunkel GE, Zhou Q, Treacy JW, Montgomery HR, Salas-Ambrosio P, Ready AD, Spokoyny AM, Houk KN, Maynard HD. Kunkel GE, et al. Bioconjug Chem. 2024 Jun 19;35(6):744-749. doi: 10.1021/acs.bioconjchem.4c00202. Epub 2024 May 29. Bioconjug Chem. 2024. PMID: 38809040 Free PMC article.
  • Future paradigms for precision oncology.
    Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, André N, Slavc I, van Den Berg H, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J. Klement GL, et al. Oncotarget. 2016 Jul 19;7(29):46813-46831. doi: 10.18632/oncotarget.9488. Oncotarget. 2016. PMID: 27223079 Free PMC article. Review.
See all "Cited by" articles

References

    1. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–774. doi: 10.1038/nrd3229. - DOI - PubMed
    1. Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol. 2012;503:3–33. doi: 10.1016/B978-0-12-396962-0.00001-X. - DOI - PubMed
    1. Gillies SD, Lan Y, Brunkhorst B, Wong WK, Li Y, Lo KM. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol, immunother: CII. 2002;51:449–460. doi: 10.1007/s00262-002-0302-6. - DOI - PMC - PubMed
    1. Nelson AL. Antibody fragments: hope and hype. mAbs. 2010;2:77–83. doi: 10.4161/mabs.2.1.10786. - DOI - PMC - PubMed
    1. De Lorenzo C, D'Alessio G. Human anti-ErbB2 immunoagents–immunoRNases and compact antibodies. FEBS J. 2009;276:1527–1535. doi: 10.1111/j.1742-4658.2009.06896.x. - DOI - PubMed

Publication types

LinkOut - more resources